Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H19Cl2N3O3 |
| Molecular Weight | 420.289 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC=C(OC[C@H]2CO[C@@](CN3C=CN=C3)(O2)C4=C(Cl)C=C(Cl)C=C4)C=C1
InChI
InChIKey=JJAHMLRQDQLJJE-PXNSSMCTSA-N
InChI=1S/C20H19Cl2N3O3/c21-14-1-6-18(19(22)9-14)20(12-25-8-7-24-13-25)27-11-17(28-20)10-26-16-4-2-15(23)3-5-16/h1-9,13,17H,10-12,23H2/t17-,20-/m0/s1
| Molecular Formula | C20H19Cl2N3O3 |
| Molecular Weight | 420.289 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 21:25:00 GMT 2025
by
admin
on
Tue Apr 01 21:25:00 GMT 2025
|
| Record UNII |
B2LSF85ZYF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
13019744
Created by
admin on Tue Apr 01 21:25:00 GMT 2025 , Edited by admin on Tue Apr 01 21:25:00 GMT 2025
|
PRIMARY | |||
|
B2LSF85ZYF
Created by
admin on Tue Apr 01 21:25:00 GMT 2025 , Edited by admin on Tue Apr 01 21:25:00 GMT 2025
|
PRIMARY | |||
|
67914-45-8
Created by
admin on Tue Apr 01 21:25:00 GMT 2025 , Edited by admin on Tue Apr 01 21:25:00 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE |
Evidence that CYP3A4 plays a significant role in metabolism of ketoconazole is that co-administration of CYP3A4 inducers, such as phenytoin, carbamazepine, and rifampin, can cause as much as a 50% reduction in levels of ketoconazole.
MAY BE CLINICALLY SIGNIFICANT
|
